Get the Stockscreener App
0.2159
4.34%
-0.0098
After Hours:
.22
0.0041
+1.90%
Azitra Inc stock is traded at $0.2159, with a volume of 1.07M.
It is down -4.34% in the last 24 hours and down -15.33% over the past month.
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
See More
Previous Close:
$0.2257
Open:
$0.2247
24h Volume:
1.07M
Relative Volume:
0.40
Market Cap:
$3.72M
Revenue:
$1.27M
Net Income/Loss:
$-11.28M
P/E Ratio:
-0.00962
EPS:
-22.4496
Net Cash Flow:
$-10.46M
1W Performance:
-4.89%
1M Performance:
-15.33%
6M Performance:
-19.41%
1Y Performance:
-81.06%
1-Day Range:
$0.2126
$0.226
1-Week Range:
$0.2126
$0.2399
52-Week Range:
$0.2126
$1.143
Azitra Inc Stock (AZTR) Company Profile
Name
Azitra Inc
Sector
Industry
Phone
203 646 6446
Address
21 Business Park Drive, Branford
Compare AZTR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZTR
Azitra Inc
|
0.2159 | 3.89M | 1.27M | -11.28M | -10.46M | -22.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Azitra Inc Stock (AZTR) Latest News
What analysts say about Azitra Inc. stockPhenomenal wealth increase - PrintWeekIndia
Is Azitra Inc. a good long term investmentUnprecedented market success - PrintWeekIndia
What drives Azitra Inc. stock priceSky-high profits - Autocar Professional
Azitra Inc. Stock Analysis and ForecastHigh-yield market plays - Autocar Professional
Why Azitra Inc. stock attracts strong analyst attentionSafer Investing With Bigger Upside - Newser
Published on: 2025-07-22 12:38:35 - jammulinksnews.com
What makes Azitra Inc. stock price move sharplyCapital Preservation Investment Ideas - Newser
How Azitra Inc. stock performs during market volatilityShort Term Profit Focus - Newser
A Closer Look at Azitra Inc (AZTR) Stock Gains - investchronicle.com
Azitra Inc. issues new warrants in connection with stock sale - MSN
Azitra shareholders approve doubling of authorized common stock - Investing.com
Azitra shareholders approve doubling of authorized common stock By Investing.com - Investing.com Canada
Azitra Inc Approves Director Elections and Share Issuance - TipRanks
Azitra Inc Plans Stock Increase at Annual Meeting - TipRanks
Azitra reports safety data from Netherton syndrome treatment trial - Investing.com
Azitra reports safety data from Netherton syndrome treatment trial By Investing.com - Investing.com South Africa
AZTR’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
Azitra Inc Announces Positive Phase 1b Trial Results - TipRanks
Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome - PR Newswire
Azitra (NYSEAMERICAN:AZTR) Stock Price Up 2% – Still a Buy? - Defense World
Azitra Inc (AZTR) Stock: A Year of Market Fluctuations - investchronicle.com
Azitra Reveals Latest Clinical Progress: Two Novel Dermatology Treatments Take Center Stage at BIO 2025 - Stock Titan
Revolutionary Skin Microbiome Treatment Could Help Cancer Patients Stay on Life-Saving Therapy - Stock Titan
Azitra, Inc. Announces Presentation at ASCO 2025 Highlighting Clinical Trial Investigating ATR-04 for EGFRi-Associated Rash - PR Newswire
FY2025 EPS Estimates for Azitra Lifted by Zacks Small Cap - Defense World
What is Zacks Small Cap’s Forecast for Azitra Q2 Earnings? - Defense World
AZTR: ATR-04 Trial to Dose 1st Patient Mid-2025 - MSN
Azitra Inc Stock (AZTR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Cap:
|
Volume (24h):